Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219252 | 0.87 | IGF1R (0.66) | IGF1RNTRK1 | |
| SCHEMBL1164948 | 0.87 | IGF1R (0.79) | IGF1RNTRK1 | |
| SCHEMBL12649912 | 0.85 | IGF1R (0.54) | IGF1RNTRK1 | |
| SCHEMBL1164462 | 0.85 | IGF1R (0.66) | IGF1RNTRK1 | |
| SCHEMBL220033 | 0.85 | IGF1R (0.66) | IGF1RNTRK1 | |
| SCHEMBL12845968 | 0.85 | IGF1R (0.54) | IGF1RNTRK1 | |
| SCHEMBL11343375 | 0.85 | IGF1R (0.75) | IGF1RNTRK1 | |
| SCHEMBL31268282 | 0.81 | IGF1R (0.54) | IGF1RNTRK1 | |
| SCHEMBL1164160 | 0.81 | IGF1R (0.51) | IGF1RNTRK1 | |
| SCHEMBL25369530 | 0.80 | IGF1R (0.61) | IGF1RNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222256-B2 | Methods of using IGFIR and ABL kinase modulators | EXELIXIS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222256-B2 | Methods of using IGFIR and ABL kinase modulators | EXELIXIS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222256-B2 | Methods of using IGFIR and ABL kinase modulators | EXELIXIS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8211929-B2 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211929-B2 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211929-B2 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1841760-B1 | PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-1841760-B1 | PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20090232828-A1 | Methods of Using IGFIR and ABL Kinase Modulators | EXELIXIS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090232828-A1 | Methods of Using IGFIR and ABL Kinase Modulators | EXELIXIS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090232828-A1 | Methods of Using IGFIR and ABL Kinase Modulators | EXELIXIS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090131463-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| EP-2043651-A2 | METHODS OF USING IGF1R AND ABL KINASE MODULATORS | Exelixis, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1456182-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008005538-A2 | METHODS OF USING IGF1R AND ABL KINASE MODULATORS | EXELIXIS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| CN-1289486-C | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-1) | ASTRAZENECA AB (SE) | 2006-12-13 | — | — | CN | disclosed |
| CN-1617858-A | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-1) | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | IGF1R, INSR, ERBB3 | IGF1R 1/4885NTRK1 228/4885 |
| US-20090131463-A1 | NOVEL COMPOUNDS | C1R, TBXA2R, F12 | IGF1R 1655/4885NTRK1 4610/4885 |
| US-20090232828-A1 | Methods of Using IGFIR and ABL Kinase Modulators | IGF1R, ABL2, ABL1 | IGF1R 1/4885NTRK1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.